Histone Deacetylase Inhibitors
- 1 October 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 69 (14), 1911-1934
- https://doi.org/10.2165/11315680-000000000-00000
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- Requirement of HDAC6 for Transforming Growth Factor-β1-induced Epithelial-Mesenchymal TransitionJournal of Biological Chemistry, 2008
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trialBritish Journal of Cancer, 2007
- SIRT1 promotes DNA repair activity and deacetylation of Ku70Experimental & Molecular Medicine, 2007
- The Epigenomics of CancerCell, 2007
- Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorProceedings of the National Academy of Sciences, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01British Journal of Cancer, 2006
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004